8-K: Sage Therapeutics' Alzheimer's Drug Fails in Phase 2 Trial, Future Development Halted

Sage Therapeutics' dalzanemdor (SAGE-718) did not meet its primary endpoint in a Phase 2 trial for Alzheimer's disease, leading to the cessation of further development in this indication.

Summary

• Sage Therapeutics announced topline results from the Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for mild cognitive impairment and mild dementia due to Alzheimer's disease.
• The study, a 12-week, randomized, double-blind, placebo-controlled trial, did not show a statistically significant difference between the dalzanemdor and placebo groups on the primary endpoint, the WAIS-IV Coding Test score at Day 84.
• A total of 174 participants were randomized in the study.
• Dalzanemdor was generally well-tolerated, and no new safety signals were observed, with most adverse events being mild to moderate.
• Exploratory endpoints, such as RBANS total score and MoCA total score, also did not show meaningful differences between the treatment and placebo groups.
• Based on these results, Sage Therapeutics will not pursue further clinical development of dalzanemdor for Alzheimer's disease.
• Topline data from the Phase 2 DIMENSION study of dalzanemdor in Huntington's disease is expected later this year.

Sentiment

Score: 3

Explanation: The document reports a significant failure in a Phase 2 trial, leading to the halt of further development of the drug for Alzheimer's. This is a negative outcome for the company and its investors, despite the drug being well-tolerated.

Positives

• Dalzanemdor was generally well-tolerated in the study, with no new safety signals observed.
• Most treatment-emergent adverse events were mild to moderate in severity.

Negatives

• The Phase 2 LIGHTWAVE study failed to demonstrate a statistically significant benefit of dalzanemdor over placebo in Alzheimer's disease.
• The primary endpoint, the WAIS-IV Coding Test score at Day 84, was not met.
• Exploratory endpoints also did not show meaningful differences between the treatment and placebo groups.
• Sage Therapeutics has decided to halt further clinical development of dalzanemdor for Alzheimer's disease.

Risks

• The failure of the LIGHTWAVE study raises concerns about the efficacy of dalzanemdor in treating cognitive impairment.
• The upcoming DIMENSION study results in Huntington's disease may also be negative, impacting the future of dalzanemdor.
• Regulatory agencies may not agree with Sage's interpretation of data, potentially affecting the approval process.
• There are risks of delays in reporting results from the DIMENSION study.
• Adverse results or events could negatively impact further development of the drug.
• Unexpected hurdles in the development and manufacture of product candidates could arise.

Future Outlook

Sage Therapeutics expects to report topline data from the Phase 2 DIMENSION Study of dalzanemdor in people with cognitive impairment associated with Huntington's Disease later this year. The company is committed to its mission of pioneering solutions to deliver life-changing brain health medicines.

Management Comments

• Barry Greene, Chief Executive Officer of Sage Therapeutics, stated that while they are disappointed by the results of the LIGHTWAVE Study, they are grateful to participants, investigators, care partners, patient advocates and the Alzheimer's community.
• He also expressed hope that their work and findings will help inform future research.

Industry Context

The failure of dalzanemdor in this Phase 2 trial highlights the challenges in developing effective treatments for Alzheimer's disease, a complex and devastating condition. This result may impact investor sentiment towards other companies developing similar treatments. The industry continues to seek new approaches to address the unmet needs in brain health.

Comparison to Industry Standards

• The failure of dalzanemdor in the LIGHTWAVE study contrasts with recent positive results from other companies in the Alzheimer's space, such as Biogen and Eisai's Leqembi, which has shown modest but statistically significant slowing of cognitive decline.
• Other companies like Eli Lilly are also advancing Alzheimer's treatments, and the competitive landscape is intense, with varying degrees of success in clinical trials.
• The lack of statistically significant results in the LIGHTWAVE study is a setback for Sage Therapeutics, especially when compared to the progress made by competitors in the field.

Stakeholder Impact

• Shareholders may experience a negative impact due to the failure of the LIGHTWAVE study and the halt of further development of dalzanemdor for Alzheimer's disease.
• Patients and the Alzheimer's community may be disappointed by the lack of progress in finding new treatment options.
• Employees of Sage Therapeutics may face uncertainty regarding the future direction of the company's research and development efforts.

Next Steps

• Sage Therapeutics will focus on the topline data from the Phase 2 DIMENSION study of dalzanemdor in Huntington's disease, expected later this year.
• The company will continue to advance its pipeline to target unmet needs in brain health.

Key Dates

Keywords

Dalzanemdor, SAGE-718, Alzheimer's Disease, Mild Cognitive Impairment, Dementia, Clinical Trial, Phase 2, LIGHTWAVE Study, Huntington's Disease, Cognitive Impairment, Biopharmaceutical